Log In
BCIQ
Print this Print this
 

DI-Leu16-IL2

  Manage Alerts
Collapse Summary General Information
Company Provenance Biopharmaceuticals Corp.
DescriptionDe-immunized form of the Leu16 anti-CD20 antibody fused to IL-2
Molecular Target CD20
Mechanism of ActionBinds CD20; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL); Treat relapsed/refractory non-Hodgkin's lymphoma (NHL)
Regulatory Designation
PartnerAlopexx Oncology LLC;
Merck KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$8.0M

$8.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/02/2012

$8.0M

$8.0M

0

03/23/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today